SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Uziely B, Jeffers S, Isacson R, et al. Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies. J Clin Oncol. 1995; 13: 17771785.
  • 2
    Rivera E, Valero V, Syrewicz L, et al. Phase I study of stealth liposomal doxorubicin in combination with gemcitabine in the treatment of patients with metastatic breast cancer. J Clin Oncol. 2001; 19: 17161722.
  • 3
    Tobias DH, Runowicz C, Mandeli J, et al. A phase I trial of gemcitabine and Doxil for recurrent epithelial ovarian cancer [Abstract]. Proc Am Soc Clin Oncol. 2000; 19: 392a.
  • 4
    Burstein HJ, Ramirez MJ, Petros WP, et al. Phase I study of Doxil and vinorelbine in metastatic breast cancer. Ann Oncol. 1999; 10: 11131116.
  • 5
    Woll PJ, Carmichael J, Calvert AH, et al. Doxil/Caelyx plus paclitaxel in patients with metastatic breast cancer: update of a phase II efficacy and safety study [Abstract]. Proc Am Soc Clin Oncol. 2001; 20: 67b.
  • 6
    Saprano JA, Malik U, Rajdev L, et al. Phase I trial of pegylated liposomal doxorubicin and docetaxel in advanced breast cancer. J Clin Oncol. 2001; 19: 31173125.
  • 7
    Ryan CW, Fleming GF, Janisch L, et al. A phase I study of liposomal doxorubicin (Doxil) with topotecan. Am J Clin Oncol. 2000; 23: 297300.
  • 8
    Abbruzese JL, Grunewald R, Weeks EA, et al. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol. 1991; 9: 491498.
  • 9
    Fossella FV, Lippman SM, Shin DM, et al. Maximum-tolerated dose defined for single-agent gemcitabine: a phase I dose-escalation study in chemotherapy-naive patients with advanced non-small-cell lung cancer. J Clin Oncol. 1997; 15: 310316.
  • 10
    Perez-Manga G, Lluch A, Alba E, et al. Gemcitabine in combination with doxorubicin in advanced breast cancer: final results of a phase II pharmacokinetic trial. J Clin Oncol. 2000; 18: 25452552.
  • 11
    Dodd PM, McCaffrey JA, Hilton S, et al. Phase I evaluation of sequential doxorubicin + gemcitabine then ifosfamide + paclitaxel + cisplatin for patients with unresectable or metastatic transitional cell carcinoma of the urothelial tract. J Clin Oncol. 2000; 18: 840846.
  • 12
    Singal PK, Iliskovic N. Current concepts: doxorubicin-induced cardiomyopathy. N Engl J Med. 1998; 339: 900905.
  • 13
    Hengge UR, Esser S, Rudel HP, et al. Long-term chemotherapy of HIV-associated Kaposi's sarcoma with liposomal doxorubicin. Eur J Cancer. 2001; 37: 878883.
  • 14
    Safra T, Muggia F, Jeffers S, et al. Pegylated liposomal doxorubicin (Doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2. Ann Oncol. 2000; 11: 10291033.
  • 15
    Carmichael J, Possinger K, Phillip P, et al. Advanced breast cancer: a phase II trial with gemcitabine. J Clin Oncol. 1995; 13: 27312736.
  • 16
    Santoro A, Bredenfeld H, Devizzi L, et al. Gemcitabine in the treatment of refractory Hodgkin's disease: results of a multicenter phase II study. J Clin Oncol. 2000; 18: 26152619.
  • 17
    Patel S, Gandhi V, Jenkins J, et al. Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation. J Clin Oncol. 2001; 19: 34833489.
  • 18
    vonMinckwitz G, Bauknecht T, Visseren-Grul CM, et al. Phase II study of gemcitabine in ovarian cancer. Ann Oncol. 1999; 10: 853855.